Doctor of Optometry Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ian Kawamoto

Optometrist Hilo, HI Doctor of Optometry

NPI 1972589273 CMS profile 270992

34 W Kawailani St, Hilo, HI 96720

Open in the dashboard

General payments

$1,191

17 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ian Kawamoto of Hilo, HI is reported in the CMS Open Payments database as having received $1,191 across 17 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 65th percentile of Optometrist profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $308 2
2024 General $550 5
2023 General $27 2
2022 General $66 1
2020 General $111 4
2019 General $130 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ian Kawamoto
  • Optometrist median
  • Middle half of Optometrist
  • National median

In program year 2025, general payments to Ian Kawamoto were reported at $308. Among 35,373 Optometrist profiles paid that year, the median was $204 and the middle half received between $87 and $464.

Show as a table
Year Ian Kawamoto Optometrist median Middle half National median
2019 $130 $159 $67–$371 $163
2020 $111 $72 $29–$165 $114
2021 $0 $125 $46–$292 $132
2022 $66 $162 $66–$374 $149
2023 $27 $177 $72–$406 $160
2024 $550 $188 $77–$427 $164
2025 $308 $204 $87–$464 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Alcon Vision LLC $330 3 payments
  2. Glaukos Corporation $285 2 payments
  3. AbbVie, Inc. $210 4 payments
  4. Amgen Inc. $125 1 payment
  5. Bausch & Lomb, a division of Bausch Health US, LLC $114 2 payments
  6. Allergan Inc. $69 3 payments
  7. Sight Sciences, Inc. $43 1 payment
  8. Johnson & Johnson Vision Care, Inc. $16 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,191 17 payments
Products named General payments · program years 2019–2025
  1. HYDRUS Microstent $264 2 payments
  2. iDoseTR $183 1 payment
  3. TEPEZZA $125 1 payment
  4. VYZULTA $114 2 payments
  5. iDose $102 1 payment
  6. DURYSTA $98 1 payment
  7. XEN GLAUCOMA TREATMENT SYSTEM $86 1 payment
  8. RESTASIS $69 3 payments
  9. Clareon $66 1 payment
  10. OMNI $43 1 payment
  11. Other $115 9 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 9 drugs

Part D claims

521

Median for Optometry: 120

Drug cost

$76,777

Median for Optometry: $8,864

Branded share of claims

19%

Median for Optometry: 24.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Restasis Cyclosporine Brand 17 $22,487
Xiidra Lifitegrast Brand 14 $21,722
Restasis Multidose Cyclosporine Brand 17 $13,825
Brimonidine Tartrate Generic 28 $5,710
Latanoprost Generic 281 $5,631
Loteprednol Etabonate Generic 25 $3,327
Azelastine Hcl Generic 64 $2,986
Dorzolamide-Timolol Dorzolamide Hcl/Timolol Maleat Brand 51 $815
Timolol Maleate Generic 24 $274

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 27,653 Part D prescribers listed as Optometry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 28 billing codes

Paid by Medicare

$78,533

Medicare's payments for the services billed

Medicare patients

399

Average age 73

Services billed

1,636

230 women, 169 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 66%
Diabetes 31%
Arthritis 28%
Chronic kidney disease 24%
Osteoporosis 16%
Atrial fibrillation 14%
Ischemic heart disease 12%
Depression 10%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DURYSTA
  • AbbVie, Inc. $98
$98 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

17 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Optometrist in Hawaii

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record